Mankind Pharma Q1 FY27 Earnings Call — Analysis (NSE: MANKIND)
Mankind Pharma Q1FY27 revenue up 13% YoY to ₹4,031 Cr with EBITDA margin expanding 250bps to 26.3%, driven by chronic portfolio growth and acute recovery; management reaffirmed FY27 margin guidance.
The take
Q1FY27 Revenue from operations ₹4,031 Cr ( +12.9% YoY ) . New guidance — FY27 fy27 capex-to-revenue ratio 6%-7% . New story: Chronic portfolio expansion towards 50% mix .
Results
Revenue ₹4,031 Cr +12.9% YoY; EBITDA margin 26.3% (+250bps YoY); PAT ₹574 Cr +29.1% YoY; domestic business excl. Consumer Healthcare +11% YoY to ₹3,180 Cr; international +29% YoY to ₹605 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue from operations | ₹4,031 Cr | +12.9% | yoy · Q1FY27 |
| EBITDA | ₹1,060 Cr | yoy · Q1FY27 · EBITDA margin improved to 26.3% from 23.8% in Q1FY26 | |
| EBITDA margin | 26.3% | +250bps | yoy · Q1FY27 |
| PAT | ₹574 Cr | +29.1% | yoy · Q1FY27 |
| PAT margin | 14.2% | +170bps | yoy · Q1FY27 |
| Gross margin | 72.8% | +230bps | yoy · Q1FY27 |
| Domestic business revenue (total) | ₹3,426 Cr | +10.5% | yoy · Q1FY27 |
| Domestic business excl. Consumer Healthcare | ₹3,180 Cr | +11% | yoy · Q1FY27 |
| Consumer Healthcare revenue | ₹246 Cr | yoy · Q1FY27 · soft growth impacted by discounted cash-and-carry discontinuation | |
| International revenue | ₹605 Cr | +29% | yoy · Q1FY27 |
| R&D spend | ₹98 Cr | yoy · Q1FY27 · 2.4% of sales vs 2.2% in Q1FY26 | |
| Capex spend | ₹198 Cr | yoy · Q1FY27 · Q1FY26: ₹127 Cr | |
| Cash EPS | ₹19.2 | yoy · Q1FY27 · Q1FY26: ₹15.9 | |
| Diluted EPS | ₹13.7 | none · Q1FY27 · per share of ₹1 | |
| Net debt | ₹3,377 Cr | point_in_time · Q1FY27 · as of 30 Jun 2026 | |
| Net operating working capital days | 52 days | +4 days | yoy · Trailing 12 months ending Q1FY27 · Q1FY26: 48 days |
Guidance
FY27 EBITDA margin maintained at 25.5%-26.5% with gross margin >71%; domestic business to grow double-digit and progressively outperform IPM; BSV guided to high-teen growth; Consumer Healthcare recovery to high single-digit to double-digit from Q2FY27.
What management committed to
- Mankind's domestic business will grow at a double-digit rate and progressively outperform IPM growth in FY27. — double-digit; outperform IPM, FY27
- FY27 EBITDA margin will be in the range of 25.5% to 26.5%. — 25.5%-26.5%, FY27
- FY27 gross margin will be above 71%. — >71%, FY27
- FY27 R&D spend will be 2.8%-3.0% of sales. — 2.8%-3.0%, FY27
- FY27 capex will be 6%-7% of total revenue. — 6%-7%, FY27
- BSV business will deliver high-teen revenue growth in FY27 (domestic ~17%, international ~25%). — high teens; domestic ~17%, international ~25%, FY27
- Consumer Healthcare revenue growth will be high single-digit to double-digit from Q2FY27 onwards. — high single-digit to double-digit, FY27
- Mankind will fully repay the acquisition-related debt (BSV) by FY28. — FY28
- Chronic portfolio share (ex-BSV) will reach 50% over the next 4-5 years. — 50%, FY31-32
- International business (ex-BSV) will grow at high teens in constant currency terms in FY27. — high teens, FY27
Key themes
Chronic-led margin expansion and acute recovery
How the narrative shifted
- Chronic portfolio expansion towards 50% mix: Management positions the shift toward chronic and specialty therapies as a structural driver of sustainable, higher-quality growth, with cardiac and anti-diabetic leading the charge.
- Acute portfolio recovery after field force reset: The deep field force correction is behind, and acute therapy growth has progressively normalized to IPM levels, restoring the 60% acute component of the portfolio.
- BSV specialty high-teen growth momentum: BSV is delivering the guided high-teen growth, driven by gynaecology/IVF depth, demand creation through clinical studies, and international market approvals.
- GLP-1 competitive landscape and strategic delay: Management frames the deliberate semaglutide launch delay as a strategic move to avoid an unprofitable price war, instead building a therapy-led approach through top KOLs.
- Consumer healthcare channel shift to modern trade/e-commerce: Despite soft headline growth after discontinuing cash-and-carry, the consumer business is gaining share in modern trade and e-commerce, reflecting channel evolution.
- Margin expansion with commodity/currency caution: Gross margin benefited from price hikes, mix, and base effects, but management warns of compression ahead from rising commodity prices and dollar strength, while maintaining full-year margin guidance.
- Debt paydown and financial discipline: The company repaid a significant NCD tranche and remains on track to clear acquisition-related debt by FY28, supporting a strong balance sheet narrative.
Operational commentary
- Chronic portfolio share (ex-BSV) rose 80bps YoY to 40%, driven by 19.4% growth in cardiac and 12.7% in anti-diabetic; management targets 50% chronic mix in 4-5 years.
- BSV business grew 21% in Q1FY27 (domestic ~17%, international ~25%); Foligraf and Humog IVF portfolio up 39%, Dydroboon up 20%, gynaec coverage expanded from 33k to 37k doctors; FSH approval received in Russia, further international approvals expected.
- Acute portfolio recovered to 10.9% growth (broadly in line with IPM) from 6.1% in Q1FY26; Gastro +13.6% (1.2x IPM), VMN +19.3%, anti-infectives turned positive at 3.6%.
- Field force reorganisation completed; attrition and vacancies normalised to historical levels, supporting sequential quarterly growth improvement.
- New specialty division ‘Vistar’ launched to scale lesser-focused brands in existing divisions.
- GLP-1 (semaglutide) delayed launch strategy: opted not to enter first wave due to hypercompetitive price war; now launched in anti-diabetes and gynaec divisions with a therapy-approach (protein + supplements), expecting gradual uptake.
- Consumer Healthcare discontinued cash-and-carry business to protect general trade; modern trade & e-commerce share rose to 15% (from 11% YoY) with 38% growth; market shares gained in Manforce, Preganews, Gas-o-fast.
- Acquired Rivotril (clonazepam) brand from Roche, CNS portfolio entry; IQVIA size ~₹20-30 Cr, aspiration to build gold CNS portfolio over time.
- International growth of 29% supported by BSV (+25%), US launches, and currency tailwinds; constant currency growth guided high teens.
- Prescription leadership maintained: #1 in IPM with 15.2% prescription share; covered market increased to 74% in anti-diabetes from 56% in FY21, with rank improving to 7.
- AI-led drug discovery partnership with Denovo Science to strengthen innovation pipeline.
- Net debt reduced to ₹3,377 Cr; repaid NCD tranche of ₹1,250 Cr in Q1; acquisition-related debt repayment on track for FY28.
Analyst Q&A
Q. What is the cash EPS if only acquisition-related amortization (BSV) is removed, similar to industry practice?
Total depreciation is ~₹225 Cr, broadly 50% is acquisition-related. We can do the calculation and share with you the numbers subsequently.
Q. Why is Mankind cautious on launching GLP-1 (semaglutide) given past aggression in new launches?
It is a strategic, not cautious, approach. We saw >20 companies, 35-40 brands, and a severe price war; we are promoting through top KOLs with a therapy approach (protein + supplements) in two divisions. Let the storm pass.
Q. Can we expect Mankind to consistently outperform IPM going forward with the field force changes and long-term drivers?
Yes, we will definitely grow double-digit. The measures will progressively deliver IPM outperformance, but recovery is gradual on a strong foundation.
Q. Is the covered market decline a meaningful driver of the gap between Mankind's growth and IPM growth?
New introduction contribution was softer (2.8% vs IPM 4.1%) partly due to GLP-1 not being launched; overall covered market has increased significantly (e.g., anti-diabetes from 56% to 74%).
Research and educational content only. Not investment advice.